Program
YK012
A development code.
Its studies are mostly in Glomerulonephritis, Membranous · Burkitt Lymphoma · Lupus Erythematosus, Systemic, led by Excyte Biopharma.
Furthest: phase 2, since Aug 26, 20245 company-led studies, 5 open or runningNext primary completion: Dec 2026 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Excyte Biopharma | 55 open or running | phase 2since Aug 26, 2024 | Aug 19, 2024 | Dec 2026phase 1 · NCT06982729 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 19, 2024First study: phase 1 study in RecurrenceFirst studyNCT06565689 · 48 planned · China
- Aug 26, 2024Phase 2 study in Burkitt LymphomaNCT06580301 · 46 planned · China
- May 6, 2025Phase 1 study in Primary Membranous NephropathyNCT06982729 · 72 planned · China
- May 30, 2025Phase 2 study in Lupus Erythematosus, SystemicNCT07010835 · 189 planned · China
- Nov 14, 2025Phase 1 study in Primary Membranous NephropathyNCT07234474 · 66 planned
Ahead
- Dec 2026Primary completion: phase 1 study in Primary Membranous NephropathyNCT06982729
- Dec 31, 2026Primary completion: phase 2 study in Burkitt LymphomaNCT06580301
- Jun 2027Primary completion: phase 2 study in Lupus Erythematosus, SystemicNCT07010835
- Oct 2028Primary completion: phase 1 study in Primary Membranous NephropathyNCT07234474
TargetBeta
“A Phase I Study of YK012, a Humanized CD19 × CD3 Bispecific Antibody, in Participants With Very High-Risk, Refractory Primary Membranous Nephropathy”study text, by rule · the study
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| blinatumomabrule | Amgen | phase 4 | 29 |
| surovatamig | AstraZeneca | phase 3 | 10 |
| Anti-CD19/CD3 Bispecific Antibody MK-1045 | Merck | phase 3 | 8 |
| GSK5926371 | GlaxoSmithKline | phase 2 | 2 |
| Anti-CD19/CD3 T-cell Engaging Bispecific Antibody CLN-978rule | cullinan-therapeutics-inc | phase 1 | 4 |
| Anti-CD19/Anti-CD3/Anti-CD28 Trispecific Antibody CC312rule | cytocares-inc | phase 1 | 4 |
| Anti-CD19/Anti-CD3/Anti-CD2 Trispecific Antibody PIT565 | Novartis | phase 1 | 3 |
| ATG-201rule | antengene-biologics-limited | phase 1 | 1 |
| KT501rule | kali-therapeutics-inc | phase 1 | 1 |
| KT502rule | kali-therapeutics-inc | phase 1 | 1 |
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07234474Primary Membranous Nephropathy | 1 | Not yet recruiting | Oct 2028 | 66 |
| NCT07010835Lupus Erythematosus, Systemic · China | 2 | Recruiting | Jun 2027 | 189 |
| NCT06982729Primary Membranous Nephropathy · China | 1 | Recruiting | Dec 2026 | 72 |
| NCT06580301Burkitt Lymphoma · China | 2 | Recruiting | Dec 31, 2026 | 46 |
| NCT06565689Recurrence · China | 1 | Recruiting | Dec 2028 | 48 |
How it is read
Names in the registry
- “YK012”, 5 entries
Codes read as this program: YK012.
Conditions, from the studies’ own filings
- Glomerulonephritis, Membranous, 2 studies
- Burkitt Lymphoma, 1 study
- Lupus Erythematosus, Systemic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.